On June 30, 2021, Qingdao Baheal Medical Inc. (refer ro “Baheal Medical”, Stock Code: 301015) landed on ChiNext Board of Shenzhen Stock Exchange. On the first day of listing, the stock of Baheal Medicine opened at RMB 35.10 per share, up 359.42%.

(May 13, 2021, Shanghai, China) During the China Beauty Expo, Qingdao Baheal Medical INC. (hereinafter referred to as "Baheal Medical") announced the launch of the country's first commercialization platform for efficacious cosmetics. Baheal Medical is committed to empowering efficacious cosmetic brands to enter the market from three dimensions: medical access standards, consumer experience upgrade, and precise marketing solutions.

On April 16, the "Future Healthcare 100" list was announced at the 5th Future Healthcare 100 Conference. Baheal Intelligent Technology, Easy Referral and Suzhou CHBiomedical, which are incubated by Baheal Investment, a subsidiary of Baheal Pharmaceutical Group, were all honored in the "Future Healthcare Rankings Top 100" list. In addition, Mr. Fu Gang, Chairman of Baheal Pharmaceutical Group, was awarded the "2020-2021 Future Healthcare VB100 - WELAN Award -Best Performing Entrepreneur in Health

On March 30, CSL Behring, a global leader in biotherapeutics, announced at the CSL Behring Blood Products Retail Summit that it has partnered with Qingdao Baheal Medical Co. Ltd. ("Baheal Medical"). The two companies will work together to provide effective and accessible drug solutions to Chinese patients.This is another important product of CSL Behring undertaken by Baheal's third-party commercialization platform, following the cooperation of human albumin products AlbuRx and Behring®. By now,

On March 29, Roche China and Qingdao Baheal Medical Co. Ltd. ("Baheal Medical") announced partnership in oncology field. Roche has granted the marketing rights of its two major oncology products, Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets), to Baheal Medical in mainland China to promote the market layout of oncology drugs, enhance product accessibility and serve the majority of oncology patients in China.